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Abstract 
β-thalassemias  are  heterogeneous  heredi-
tary anemias characterized by a reduced out-
put of β-globin chains.  The disease is most
frequent in the temperate regions of the world,
where it represents an important health prob-
lem.  In  the  last  decades,  several  programs,
aimed  at  controlling  the  birth  rate  of  tha-
lassemia newborns by screening and prenatal
diagnosis of populations with high risk of β-
thalassemia,  have  been  successful  accom-
plished.  Bone  marrow  transplantation  has
offered  a  definitive  cure  for  the  fraction  of
patients  with  available  donors.  In  the  same
time, steady improvements were made in the
traditional  clinical  management  of  β-tha-
lassemia patients.  The introduction of the oral
iron chelators deferiprone that preferentially
chelates hearth iron and the development of
novel  NMR  diagnostic  methods    has  led  to
reduced  morbility,  increased  survival  and
improved quality of life.  More recently, major
advances have being made in the discovery of
critical modifier genes, such as Myb and espe-
cially BCL11A (B cell lymphoma 11A), a master
regulator of HbF (fetal hemoglobin) and hemo-
globin switching.  Polimorphysms of BCL11A,
Myb and γ-globin genes account for most of the
variability in the clinical phenotypes in β-tha-
lassemia  and  sickle  cell  anemia  patients.
Finally, the year 2010 has brought in the first
successful experiment of gene therapy in a β-
thalassemia patient, opening up the perspec-
tive of a generalized cure for all β- thalassemia
patients. 
Introduction 
β-thalassemias, a group of autosomal reces-
sive  disorders  resulting  from  reduced  or
absent production of β-globin chains from the
β-globin locus, are very heterogeneous at the
molecular level (for review see Weatherall &
Clegg, 2001 and Cao & Galanello).1,2More than
200  disease-causing  mutations  have  been
described to date. The large majority of muta-
tions  are  simple  nucleotide  substitutions  or
deletions  or  insertions  of  oligonucleotides
leading  to  frameshift.  Rarely  the  β-tha-
lassemias are the result of gross gene dele-
tions. Homozygosity for β-thalassemia usually
leads to the severe transfusion-dependent phe-
notype of thalassemia major. Treatment with a
regular  transfusion  program  and  chelation
therapy,  aimed  at  reducing  the  transfusion
iron-overload  allows  for  normal  growth  and
development and extends the life expectancy
into the third to fifth decade. Bone marrow or
cord blood transplantation (BMT) from an HLA
(human leukocyte antigen) -identical sib rep-
resent an alternative to traditional transfusion
and chelation therapy. More rarely the homozy-
gous state for β-thalassemia leads to the phe-
notype of thalassemia intermedia. Individuals
with thalassemia intermedia present later, and
have  milder  anemia  and  only  rarely  require
transfusion. However also patients with tha-
lassemia intermedia are at risk to develop iron
overload secondary to increased intestinal iron
absorption  because  of  ineffective  erythro-
poiesis. 
In the last few years there has been a dra-
matic  advancement  in  the  field  of  chelation
therapy, genetic factors ameliorating the clini-
cal  phenotype,  hemoglobin  switching,  gene
therapy  with  lentiviral  vectors  and  develop-
ment of embryonic-like stem cells obtained by
transfection and reprogramming differentiat-
ed somatic cells with key regulatory factors.  All
these developments, which are the topics of
this  review,  may  lead  in  the  long  term  to
advances in the traditional and in the gene and
stem-cell-based therapy.
Genetic modifier factors 
in β-thalassemias
As alluded in the introduction, homozygotes
or compound heterozygotes for β-thalassemia
usually result in the phenotype of transfusion-
dependent thalassemia major. However, in a
consistent proportion of the cases, these inter-
mediate genotypes are associated with milder
forms, which are referred to as thalassemia
intermedia.  These  forms  of  β-thalassemias
show  a  marked  phenotypic  heterogeneity
which  ranges  from  the  severe  thalassemia
major to the asymptomatic β-thalassemia car-
rier state.1-4 Genetic determinants capable of
ameliorating the phenotype of β-thalassemia,
so far defined (Figure 1), exert their effect by
reducing the α/nonαchain imbalance, thereby
resulting in a lesser degree of α-chain precip-
itation,  which  is  the  critical  factor  in  the
pathophysiology of these inherited anemias.5,6
A well-recognized mechanism for the pro-
duction of a milder phenotype is the inheri-
tance of a mild or silent β-thalassemia muta-
tion, in homozygosity or in a compound het-
erozygous state with a severe mutation. Mild
and silent mutations are molecular defects of
the β-globin gene associated with a consistent
residual  output  of  β-globin  chains  from  the
affected β-locus.
A  second  characterized  molecular  mecha-
nism is the co-inheritance with homozygous
β-thalassemia  of  mutations  of  the  α-globin
gene associated with α-thalassemia which by
reducing the output of α-chains decrease the
α/nonα chain imbalance. 
A  third  mechanism  is  related  to  the  co-
inheritance  of  genetic  determinants  able  to
substain a persistent production of γ-chain in
the adult life, which again act by reducing the
α/nonα globin chain imbalance. 
Rarely  the  increase  of  γ-chain  output
depends on the type of thalassemia mutation
per se as it occurs in δβ-thalassemias caused
by deletions of variable extent in the β-globin
gene cluster or in deletions removing the HBB
promoter.
Most commonly the persistence of HbF pro-
duction depends on the co-transmission of a
specific determinant of hereditary persistence
of  fetal  hemoglobin  (HPFH).  The  inherited
persistent  production  of  HbF  in  adult  life
belongs to two different categories according
to the distribution of HbF within the red blood
cells, which can be pancellular (homogeneous
distribution) or heterocellular (heterogeneous
distribution).  Pancellular  HPFH  are  caused
either by deletion at variable extent of the β-
globin cluster or by point mutation in the Gγ or
Aγ promoter.
Heterocellular  HPFH  are  associated  with
quantitative trait loci linked or unlinked to the
β-globin cluster.7 These heterocellular HPFH
determinants  were  recently  shown  to  play  a
major role in determining the phenotype of β-
thalassemia (Table 1).
Hemoglobin F regulation
The  residual  amount  of  HbF  in  normal
adults  is  distributed  heterogeneously  in  the
red blood cells of which those showing a meas-
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urable quantity are dubbed F cells.8 The level of
HbF and the F cell count are strictly correlated
and show a similar distribution. The majority
of normal adult individuals have usually HbF
levels <0.6% of the total Hb; however 10-15%
show higher levels ranging between 0.8 and
5% of total Hb. As alluded before, these sub-
jects are considered carriers of heterocellular
HPFH genetic determinants.9
Twin studies have clearly demonstrated that
HbF is a highly heritable trait. Genetic factors
appear indeed responsible for 89% of the FC
variance.9
Gγ promoter QTLs associated with
heterocellular HbF 
Since many years genetic determinants of
high HbF production have been recognized in
the β-globin gene cluster within the Aγ and Gγ
promoter.10 In non-anemic subjects from North
Europe the XmnI SNP (Single nucleotide poly-
morphysm) at position -158 upstream of the
transcription start site of HBG2 (now denomi-
nated rs7482144) accounts for 13-32% of F-cell
variance11 (Figure 2). 
The effect of the -158 CₒT determinant is,
however not consistent, being associated also
with normal HbF levels both in normal individ-
uals as well as in β-thalassemia heterozygotes.
In  contrast  in  conditions  of  erythropoietic
stress,  as  occurring  in  homozygous  β-tha-
lassemia or in sickle cell anemia,12 the Gγ-158
CₒT mutation may lead to high production
rate of HbF, thereby playing a role in the ame-
lioration of the phenotype. For instance some
β-globin mutations, i.e. codon 6 -A and codon 8
–AA, which are in linkage disequilibrium with
the Gγ -158 CₒT, are consistently associated
with  higher  HbF  production  and  evolution
toward the clinical phenotype of thalassemia
intermedia.  
The role of the Gγ 158 CₒT polymorphism
as a quantitative trait locus for HbF has recent-
ly  been  confirmed  by  genomic  association
studies. By GWA (Genome wide association)
studies  the  trait  variance  attributed  to  this
locus was 10.2% in Northern Europeans.13-14
The mechanisms of the Gγ -158 CₒT variance
on the HbF level is not well defined, but may be
related to an elevated Gγ gene expression.
Fine  mapping  of  this  region  in  African-
Americans with sickle cell anemia found a SNP
rs10128556  located  downstream  of  HBG1,
more strongly associated with HbF levels than
rs7482144-XmnI  indicating  that  at  least  in
African-Americans the rs7482144-XmnI is not
the causal variant.15 Similarly, in Sardinias a
different  SNP  mapped  in  the  HS3
(Hypersensitive  site  3)  of  the  locus  control
region  of  the  β-globin  gene  cluster
(rs4910742), which is not in linkage disequi-
librium with the rs7482144-XmnI, accounts for
2.58% of the HbF variance.14
6q QTL locus
In  addition  to  the  β-globin  gene  cluster,
positional  cloning  and  successive  genome-
wide linkage analysis of an Asian-Indian kin-
dred family with β-thalassemia and an inde-
pendently  segregating  high  HbF  trait  led  to
map a quantitative HbF trait locus on chromo-
some 6q23-q24 (Figure 2).  This trait appeared
to  be  associated  with  the  development  of  a
mild β-thalassemia phenotype.16,17
Later on, high resolution association map-
ping in families of Northern European ances-
try identified multiple genetic variants in the
1.5  Mb  6q23-q24  interval  on  chromosome  6
strongly associated with F cell levels (P=10-
75). This variant maps in the intergenic region
between  the  HBS1L  gene  and  the  MYB
(myeloblastosis)  oncogene  and  accounts  for
∼19% of the population trait variance,13in this
population.  In  African-Americans  with  sickle
cell anemia, haplotypes defined by three SNPs
mapping at this locus explained more variation
in HbF levels than the cumulative sum of the
phenotypic  variance explained by the SNPs
individually  (7.3%  versus  6.8%,  difference
however  not  significant).15 Resequencing  of
the HBSA11L and MYB genes mapping in this
region detected several missense variants in
both genes. However, a significant difference
for  MYB  was  detected  in  carriers  with  high
HbF versus non carriers, indicating that most
likely MYB is causally involved in controlling
HbF.15 The  mechanism  regulating  the  Hb  F
level of this locus has not been so far defined.
Recent studies by chromatin immunoprecipi-
tation with microarray analysis (ChIP-chip) in
primary  human  erythroid    precursors  have
shown  within  this  region  the  presence  of
strong histone acetylation, GATA-1 recognition
motifs,  coincident  with  DNAse  1  sites  and
associated with intergenic transcription, sug-
gesting the existence of a regulatory region
controlling  the  MYB  expression.18 The  ery-
throid  precursors  of  individuals  with  high  F
have low MYB expression. In addition to HbF
level, this region influences also the erythro-
cyte count and volume and the platelet count. A
further contribution of the role of MYB in con-
trolling HbF variation comes from a study on
the mechanism of delayed switching and per-
sistence  of  HbF  in  human  trisomy  13
patients.19 By using partial trisomy cases the
HbF trait was mapped to chromosomal band
13q14. Examination of this region showed two
microRNA (miR15a and -16.1), as candidate
Review
Table 1.  Genetic conditions with increased
HbF in adult life.
Deletion
-δβthalassemia
-HPFH
Non deletion
Linked to the β-cluster
Gγpromoter mutations
Aγpromoter mutations
Unlinked to the β-cluster
-6q23
-2q15
HbF, fetal hemoglobin; HPFH, hereditary persistence of fetal hemo-
globin.
Figure 1. Genetic modifying factors in β-
thalassemia.  Modifying  factors  generally
act by reducing or increasing the altered
globin  biosynthetic  ratio  typical  of  tha-
lassemia.
Figure 2. HbF associ-
ated SNPs. Chromo  -
some  bands,  associ-
ated genes and rela-
tive  SNP  positions
are  indicated.
Variance of the HbF
(H2)  in  the
Sardinian  popula-
tion  is  shown  in
parenthesis  for  the
SNPs with the high-
est  association  at
each  locus.  SNP,
Single  nucleotide
polymorphysm;
HBF, fetal hemoglo-
bin.[Pediatric Reports 2011; 3:e17] [page 67]
genes for elevated HbF levels. By a combina-
tion  of  genetic  and  functional  studies  in
human  cells,  overexpression  of  miR15a/16.1
resulted in elevation of HbF expression, which
may therefore explain the delayed switch and
persistence of HbF in trisomy 13. This effect
appears mediated through downregulation of
the MYB transcription factor (a potent nega-
tive regulator of HbF expression), which is a
direct target of miR15a and miR16.1.19 These
results indicate that downregulation of MYB
expression leads to delayed switch from HbF to
HbA  (Hemoglobin  A)  and  persistent  expres-
sion of HbF.
These findings indicate that the 6q23 locus
controls the expression of MYB, which in turn
influences the kinetics of erythroid differenti-
ation  and  thereby  HbF  production.  Previous
studies  have  in  fact  demonstrated  that  the
acceleration of erythropoiesis occurring in sit-
uation  of  erythropoietic  stress  is  associated
with high HbF production.20
The role of 6 QTLs (Quantitative trait loci)
on the regulation of HbF have been later on
confirmed in normal individuals and subjects
affected by β-thalassemia and sickle  cell ane-
mia of different ancestry.14,2,22
Chromosome 2 QTLs
Genomic-wide  association  studies  carried
out in 4000 Sardinians, including normal indi-
viduals and carriers of β and α-thalassemia,
confirmed the association of HbF levels with
the β-locus (sr4910742 P <1.80ﾥ10–21) and the
MYB/HBS1L  locus  (sr135468266  P<1.20ﾥ10-
16), but also showed a strong association on
chromosome 2, in intron 2 of the BCL11A gene
(SNP sr11886868 P<6.70ﾥ10-35)14(Figure 2). A
similar result (P<1019) was obtained by geno-
typing a group of 179 individuals with extreme
FC values (above the 95th and below the 5th
percentile) selected from a cohort of 5184 indi-
viduals  of  Northern  European  ancestry.  The
BCL11A  locus  accounts  for  15.1%  of  the  FC
variability  in  Northern  European23  and  for
7.66%  of  the  HbF  variance  in  Sardinians14
(Figure 2).
Fine  mapping  at  the  BCL11A  locus  in
African-Americans  with  sickle  cell  anemia
found  three  SNPs  independently  associated
with HbF. Haplotype analysis (based on these
SNPs), indicated that haplotypes at this locus
explain  more  phenotypic  variance  than  the
cumulative sum of the three SNPs taken indi-
vidually (18.1 versus 14.7%).15
These findings were later confirmed in nor-
mal  population  of  different  ancestry,  in
Chinese and Thai carriers of β-thalassemia24
and in patients with sickle cell anemia from
USA, Brasil and UK.21 
In our studies in 1412 individuals directly
genotyped for rs11886868 (intron 2 of BCL11A)
the genotype distribution was markedly differ-
ent between individuals with high HbF levels
(>0.8% HPFH) and those with normal levels
(<0.8%).  Genotype  frequencies  were  67%
(T/T), 30% (T/C) and 3% (C/C) in individuals
with normal HbF levels (Table 2). In subjects
with  HPFH  these  frequencies  become  40%,
47% and 13% with a marked enrichment in the
C allele and the C/C genotype. Furthermore,
the C variant at rs11886868 in BCL11A locus
was more frequent in β-thalassemia homozy-
gotes with a mild phenotype (52 patients with
thalassemia  intermedia)  as  compared  with
those  with  a  severe  transfusion-dependent
form (74 patients). These findings clearly indi-
cate that the BCL11A gene is able to amelio-
rate  the  phenotype  of  homozygous  β-tha-
lassemia by increasing HbF levels (Table 2).
As in β-thalassemia, in patients with sickle
cell  disease  from  the  Cooperative  Study  of
Sickle cell disease (CSSCD), which includes
African-American  patients  with  homozygous
sickle cell disease (SS) and sickle hemoglobin
C  disease  (SC),  the  C  allele  at  marker
rs11886868  was  strongly  associated  with
increased HbF (P<10-20), accounting for 8.6%
the variance in the trait14and reduced pain cri-
sis.21
Other loci
Recent  studies  have  shown  that  polymor-
phisms in the olfactory receptor gene region
mapping upstream of the β-globin gene cluster
LCR, are associated with HbF concentration in
sickle cell anemia.25 This region may modulate
HbF levels by an effect on the chromatin struc-
ture of the β-globin cluster. On the other hand,
other loci on Xp22.2-22.3 and 8q26-28 outside
the β-globin gene cluster previously found to
affect HbF, were not supported by GWA stud-
ies.13,14
Epistasis and relative contribution
of the loci identified on HbF values
Epistasis among the various loci detected by
GWA was limited to the interaction between
pairs  of  SNPs  on  the  β-globin  locus  and
between rs4895441 on the MYB/HBS1L locus
and rs1391619 on chromosome 11.14
In  African-Americans  the  HbF  phenotypic
variation explained by the three loci on 11q, 2q
and 6q following haplotype analysis increased
from 23.5 to 30.1%.15
Recently our group has evaluated the rela-
tive contribution of BCL11A, HBS11/MYB loci
and co-inheritance of α-thalassemia, on the
clinical  phenotype  of  homozygous  β°-tha-
lassemia.22 We  confirmed  that  the  α-tha-
lassemia and  allele C of SNP rs11886868 in
BCL11A associated with high HbF were more
frequent  in  thalassemia  intermedia  versus
thalassemia  major.  Likewise  the  G  at  SNP
rs9389268 in HBS1L-MYB region associated to
elevated HbF was more represented in patients
with thalassemia intermedia. The contribution
of the three loci BCL11A, HBS11L-MYB and α-
thalassemia expressed as OR were 5.15, 4.61
and 3.31 respectively (Table 3).
These three loci act in additive fashion, with
each  copy  of  the  modulating  allele  at  each
locus contributing to the amelioration of the
clinical phenotype. In complex these genetic
factors account for 75% of the variation in phe-
notype severity.22
Our  results  are  at  variance  with  those
observed in healthy Northern European popu-
lation, where HBS1L-Myb locus has a stronger
effect than BCL11A on the F cell number.13
Genotyping at these loci in neonatal period
may have a practical utility, serving as a prog-
nostic  indicator  for  the  severity  of  β-tha-
Review
Table 2. Distribution of rs11886868 genotypes in thalassemic patients, HPFH individu-
als, and the general population from Ogliastra (Sardinia).
n Individuals C/C C/T T/T
HPFH* 66 0.227 0.546 0.227
Thalassemia intermedia 52 0.192 0.597 0.211
Thalassemia major 74 0.040 0.355 0.635
Sardinia 1,412 0.040 .0316 0.644
HPFH, hereditary persistence of fetal hemoglobin. *HPFH was detected by population screening in the entire Sardinian population.
Table 3. Summary of the association with amelioration of β°-thalassemia.
SNP/locus Allele Frequency  Frequency P OR (95% confidence
thalassemia  thalassemia interval)
major intermedia
rs11896968/BCL11A C 0.21 0.48 <.001 5.15 (2.46-12.06)
rs9389268/HBS1l-MYB G 0.15 0.35 <.001 4.61 (2.18-10.76)
HbA* - 0.25 0.52 <.001 3.32 (1.75-6.80)
For each marker, we reported the minor allele with the correspondent frequency on the 2 groups of patients, the P value for allelic differ-
ence and the odds ratio. *For the HBA locus, genotypes have been coded as 0, 1 or 2 according to the number of mutated copies of the HBA
gene. Because of small counts, persons with -α/αHpHα and -α/αNcoIα have been grouped with -α/-α, αNcoIα/αα with -α/αα
HBA, human alpha-globin gene.[page 68] [Pediatric Reports 2011; 3:e17]
lassemia  and  sickle  cell  anemia,  thereby
improving  the  genetic  counseling.
Furthermore,  targeted  manipulation  of
BCL11A in erythroid precursors may boost the
production of HbF eventually leading to cure β-
thalassemia and sickle cell anemia. 
Accordingly, transduction of CD34 cells with
lentiviral vector carrying a short hairpin RNA
(shRNA) targeting the γ-globin gene repressor
BCL11A, led to significant increase of HbF in
differentiated  erythroblasts,  around  10%  in
cells derived from normal donors and from 33
to 45% in β-thalassemic cells.29
Function of BCL11A and implication
for Hb switching
BCL11A  (B  cell  lymphoma-leukemia  11A
also dubbed EV19 (ecotropic viral integration
site 19), CTIP1 (COUP-TF-interacting protein
1) is a zinc-finger transcriptional factor neces-
sary  for  normal  B  and  T  lymphopoiesis.30
Recent  GWA  studies  mentioned  before  have
demonstrated an additional role in controlling
HbF levels in peripheral blood.14,21,23
Further  studies  have  demonstrated  in
human erythroid progenitors and in the knock-
out mouse that BCL11A functions as a regula-
tor  of  γ-globin  gene  expression.31 BCL11A
binds the HS3-LCR and the intergenic region
between  the  Aγ-globin  and  δ-globin  (Figure
3).32The Aγ-δintergenic region overlaps a pre-
viously reported deletion associated with high
HbF levels.29However, in these studies BCL11A
does not bind to the γ-globin gene promoter.  In
partial agreement with Sankaran,31,33 Jawaid
et al.,34 by ChIP-chip experiments, in mouse
basophilic  erythroblasts  cultivated  from
peripheral blood, showed BCL11A binding to
LCR-HS1, HS2, HS3 and HS7, 3’ end of HBE1,
3.4  Kb  downstream  of    HBG1  and  1.5  Kb
upstream of HBD, at OR52A1 gene, which is
∼75Kb downstream of HBB (a region which
contains a 3’ enhancer as indicated by studies
in HPFH deletion).35 Binding to LCR was usu-
ally coincident with GATA-1 binding.  In con-
trast, EMSA studies in K562 cells found bind-
ing of BCL11A to a GGCCGG motif at position -
56  to  -51  of  the  HBG2  proximal  promoter.36
However, expression of BCL11A in K562 cells
has not been consistently detected.34
BCL11A shows abundant expression in pri-
mary adult human CD34 derived erythroid pre-
cursors, where its downregulation by siRNA or
shRNA leads to marked induction of γ-chains
and thereby increased HbF.31 Genetic variants at
the BCL11A locus associated with high HbF lev-
els show a reduced expression of BCL11mRNA.
By proteomic approach, BCL11A was found to
interact physically with the NURD (Nucleosome
Remodelling  Deacetylation)  complex  (which
contains two histone deacetylase (HDAC1) and ,
the  nuclear  matrix  component  Matrin  3,  the
GATA1 and FOG1 erythroid transcriptional fac-
tors  and  the  HMG-box  protein  SOX6,  a  chro-
matin associated protein [member of the SRY-
related high mobility group (HMG) box  tran-
scription  factors]  that  binds  and  induces  a
marked bending of DNA (Figure 4).31,33,37In fetal
liver  definitive  erythroid  cells  of  the  Bcl11a
knockout  mice  the  mouse  embryonic  globin
genes  are  markedly  upregulated,  whereas  in
normal mice they are silent. Knockout of Bcl11a
transgenic mouse, carrying the human β-globin
locus, led to a failure of developmental silencing
of the mouse embryonic globin and human γ-
globin  gene.38 These  findings  indicate  the
BCL11A in cooperation with SOX6 (see later)
and  other  transcriptional  factors  is  able  to
silence the γ-globin gene, thereby actively partic-
ipating in the switching process.37
Downregulation of BCL11A expression may
lead to a new approach for activation of HbF
production in hemoglobin disorders.
Function of KLF1 (Krueppel-like
factor1) in Hb switching 
KLF1 (previously dubbed EKLF) is a zinc-fin-
ger  erythroid  transcriptional  regulator  that
binds  to  the  critical  promoter  elements
(CACCC  box)  of  the  adult  β-globin  gene.39
Knockout of Klf1 in mice leads to embryonic
lethality because of the development of severe
β-thalassemia.40-41Accordingly mutation of the
CACCC box of the human β-globin gene results
in the phenotype of the β+-thalassemia.42 Two
new  studies43-44 demonstrate  that  KLF1,  in
addition to activate the β-globin gene, down-
regulates the BCL11A gene, thereby leading to
increased γ-globin chain production. Zhou et
al.,43 by studying human and mouse adult ery-
throid  progenitors,  have  shown  that  knock-
down of Klf1 by Klf1 shRNA lentiviral vectors
leads to marked reduction of Bcl11a protein
and Bcl11mRNA and to an increase in human
γ-globin/β-globin  expression  ratio.
Furthermore,  by  ChIP  quantitative  PCR
(qPCR), they showed also that Klf1 binds the
CACCC box of the mouse Bcl11a promoter in
adult bone marrow erythroid cells, suggesting
that Klf1 directly regulates the Bcl11a expres-
sion.  Borg  et  al.44 studied  a  large  family  of
Maltese  origin  with  HFPH  by  genomic-wide
SNP analysis followed by linkage analysis and
identified a shared haplotype at 19p13.12,13 in
all  members  of  the  family  with  HPFH.
Sequencing of KLF1, mapping in this region,
revealed a nonsense mutation (K288X) abro-
gating its DNA bindings domain and segregat-
ing with the HPFH phenotype in this family.
Genomic-wide  expression  analysis  from  ery-
throid  progenitors  cultured  from  peripheral
blood showed downregulation of KLF1 target
genes,  including  BCL11A  in  all  individuals
with HPFH. Quantitative RT-PCR demonstrat-
ed,  in  addition,  increased  expression  of  the
HBG1/HBG2 genes. KLF1 knockdown by specif-
ic  lentiviral  shRNA  construct  in  human  ery-
throid precursors from healthy donors, led to
increase of HBG1/HBG2 expression and reduc-
tion in BCL11A expression. In adult erythroid
progenitors, but not in fetal liver derived ery-
throid  progenitors,  KLF1  in  addition  to  the
HBB  promoter  binds  also  strongly  to  the
BCL11A promoter. This study indicates that the
HPFH phenotype may result from KLF1 hap-
loinsufficiency and that KLF1 by regulating the
BCL11A expression indirectly influences the γ-
globin  expression.  In  accordance  with  these
studies in mouse and human, a transfusion-
dependent  congenital  dyserythropoietic  ane-
mia associated with high HbF and resulting
from  a  mutation  in  KLF1,  was  recently
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Figure 3. Regions of the β-globin cluster bound by Bcl11A in ChIP and ChIP seq stud-
ies. 
Figure 4. Schematic representation of the
most  important  partners  that  interact
with Bcl11A. [Pediatric Reports 2011; 3:e17] [page 69]
described.45 It is interesting to note that the
causative mutation E325K maps on KLF1 at the
equivalent  site  as  the  NAN  mutation  in  the
mouse which causes a severe congenital ane-
mia in this species.46
All these studies led to propose a coherent
mechanism  of  hemoglobin  switching.  In
embryonic and fetal development or in KLF1
haploinsufficient  adult  Klf1  concentration  is
reduced resulting in low levels of β-globin and
BCL11A and high levels of γ-globin. In normal
adults with two copies of KLF1, the higher lev-
els of Klf1 determines high expression of b-glo-
bin  and  BCL111A  that  represses  γ-globin
expression (Figure 5). Controlled pharmaco-
logical inhibition of KLF1 by downregulating
BCL11A and augmenting γ-chain expression,
could be explored as a strategy for ameliorat-
ing  hemoglobin  disorders  such  as  β-tha-
lassemia and sickle cell anemia. 
However, exploration of a direct pharmaco-
logical activation on BCL11A could be prefer-
able because this approach should avoid the
eventual adverse effect of inhibition of KLF1
on β-globin chain synthesis.
Iron overload assessment and
treatment
As a consequence of repeated long-life red
blood cell transfusions, essential for survival,
patients  with  thalassemia  major  accumulate
over time iron in the body. Excess iron is toxic
to many tissues, including the liver, endocrine
organs and heart, leading to a series of compli-
cations which cause morbidity and mortality in
these  patients.  Hypogonadism  reported  in
more than 50% of the patients, hypothyroidism
in 10% and hypoparathyroidism in 9%, are still
the  most  common  complications  in  tha-
lassemia  major.47 Diabetes,  heart  failure  ad
arrhythmias have been described in 6.4%, 6.8%
and 5.7% respectively.47 Liver disease, result-
ing from infections  with viruses that cause
hepatitis  B  and  C,  affects  up  to  70%  of  the
patients.  Moreover,  post-transfusional  liver
iron  overload  associated  with  viral  chronic
hepatitis increases the risk of cirrhosis and
hepatocarcinoma.48 As the body has no effec-
tive means for removing iron, the only way to
remove  excess  iron  is  to  use  iron  binders
(chelators),  which  allow  iron  excretion
through the urine and/or stool. The first drug
available for treatment of iron was deferoxam-
ine (DFO), which has been introduced in clin-
ical practice in the 70’s. Its use has significant-
ly reduced morbidity and improved survival in
patients  with  thalassemia  major.  However,
because of side effects and the inconvenient
parenteral administration (see later), a con-
sistent  proportion  of  patients  do  not  comply
with deferoxamine treatment. This is probably
the reason why iron overload related complica-
tions are still relatively frequent and the most
common cause of death in patients with tha-
lassemia major is cardiac disease. In fact, in
different groups, death for cardiac disease has
been reported in 60-70% of the patients.47,49,50
In the last years two major advances have sub-
stantially  changed  the  prognosis  of  the
patients with thalassemia major: the introduc-
tion in the clinical use of the oral iron chela-
tors  and  the  development  of  non-invasive
methods for the assessment of specific organ
iron overload.
Non-invasive assessment of organ
iron overload
The accurate evaluation of iron overload is
necessary to plan and to monitor iron chela-
tion.  Serum  ferritin  is  an  easy,  worldwide
available  and  cheap  method  to  indirectly
assess iron stores. In the absence of confound-
ing factors such as infections, liver disease,
neoplasia  and  vitamin  C  deficiency,  serial
measurements of serum ferritin allow longitu-
dinal follow-up of patients and are useful for
monitoring chelation therapy. However, serum
ferritin does not accurately reflect hepatic and
cardiac iron51,52 and since serious complica-
tions, limiting survival, may occur as a conse-
quence  of  increased  iron  content  in  these
organs, liver and heart iron assessment is rec-
ommended in patients with thalassemia major.
Liver iron concentration (LIC) can be deter-
mined  by  liver  biopsy,  but  the  procedure  is
invasive and complications requiring hospital-
ization have been reported in about 0.5% of
patients  who  undergo  liver  biopsy,  even  in
experienced centres.53 Therefore, for the asso-
ciated risks liver biopsy cannot be repeated for
routine follow-up necessary to plan and adjust
chelation  therapy.  Moreover,  distribution  of
iron in the liver seems to be heterogeneous
also in absence of cirrhosis.54,55 Magnetic bio-
susceptometry, by the superconducting quan-
tum  interference  device  (SQUID)  is  a  non-
invasive method used to measure liver iron.56
The method has been validated, but has some
disadvantages  including  underestimation  of
liver  iron  concentration,  limited  availability
(only  4  functioning  devices  are  at  moment
present in the world) and the incapability of
assessing iron in the heart. Moreover, it has
been shown that liver iron does not correlate
with heart iron in a proportion of patients.51
Measuring  cardiac  iron  is  critical  for  tha-
lassemia major patients because iron-related
cardiac  complications  (i.e.  cardiomyopathy,
congestive heart failure and arrhythmias) are
relatively  common  and  severe  and  cardiac
death is the most frequent cause of death  in
thalassemia.47,49,50 The  introduction  of  mag-
netic resonance imaging (MRI) for the assess-
ment of tissue iron in the early 2000, complete-
ly changed our understanding of iron overload
and its management.
MRI has proven effective in detecting and
quantifying iron in the heart, liver and other
organs (Figure 6). Besides being non-invasive,
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Figure 5. Current hemoglobin switching model. Globin gene activation is dependent
upon concentration of Klf1. In the fetal stage of erythroid development or at low Klf1
concentration, weakly expressed Bcl11A can not repress  γ-globin genes and Klf1 prefer-
entially interacts with the γ-globin genes that are stimulated upon  recruitment of LCR
elements.  In the adult stage or at high Klf1 concentration, overexpressed Bcl11A repress-
es  γ-globin genes and Klf1 binds preferentially the β-globin genes that are stimulated
upon recruitment of the LCR (Inactive genes are grayed, active genes are in light green).
LCR, Locus control region; KLF, Krueppel-like factor; Bcl11A: B cell lymphoma 11°.[page 70] [Pediatric Reports 2011; 3:e17]
MRI is inexpensive, widely available in devel-
oped and also in developing countries, robust
and  reproducible  in  the  clinical  relevant
range.57,58 MRI does not image the iron direct-
ly but instead images water protons desynchro-
nized  by  the  iron  deposits  in  the  tissue  of
interest.59,60 Iron  shortens  T2*  relaxation
time, which has become the most sensitive,
robust  and  therefore  most  used  measure  of
cardiac  iron.  In  2001  Anderson  et  al.61 pub-
lished  a  fundamental  paper  describing  the
relationship between cardiac T2* and left ven-
tricular ejection fraction in patients with tha-
lassemia major.61 Cardiac T2* greater than 20
milliseconds (ms) indicates normal iron con-
tent, while values between 10 and 20 ms or
lower than 10 ms indicate moderate or severe
iron  overload  respectively.  As  T2*  decreases
below 20 ms, increases the risk of having a
decline in ejection fraction, but it should be
pointed out that many patients with moderate
or even severe cardiac iron may have normal
cardiac function, suggesting that T2* is able to
identify  preclinical  cardiac  dysfunction.  In  a
large retrospective study in UK, Kirk et al.62
evaluated the relevance of heart T2* as predic-
tor of cardiac failure. Forty-seven percent of
patients with T2* lower than 6 ms developed
cardiac failure within 12 months from detec-
tion.  Identifying  at  risk  patients  before  car-
diomyopathy develops, allows the use of target-
ed iron chelation treatment to reduce cardiac
mortality.52 Prediction of arrhythmia was also
significant but of lower magnitude. 
Despite the limitation of the lack of correla-
tion between LIC and heart iron in a propor-
tion  of  patients,  assessment  of  liver  iron  is
important because iron is stored mainly in the
liver and LIC accurately reflects total body iron
stores.53 LIC can be used to monitor efficacy of
iron chelation therapy. For MRI evaluation of
liver  siderosis  different  methods,  including
signal  intensity  ratio  and  relaxometry  tech-
niques, were introduced. At present T2*, R2
and R2* methods are the most widely used, R2
and R2* being the most accurate63 MRI meth-
ods have been calibrated with LIC obtained by
liver biopsy.61,64,65 Although MRI is commonly
used  to assess liver and heart iron, it can also
be  used  to  estimate  tissue  iron  overload  in
other  organs  including  pituitary  gland  and
pancreas.  The  pituitary  gland  is  one  of  the
most  vulnerable  target  organ  to  early  toxic
effects from iron overload, leading to hypogo-
nadotropic hypogonadism in a large proportion
of patients.47,66 Pituitary R2 is closely correlat-
ed to liver and pancreatic iron, but not to heart
iron. This suggests that kinetics of pituitary
iron loading is relatively fast and starts already
in childhood.67 Pancreatic MRI-T2*Iron over-
load is thought to produce oxidative stress in
the pancreas beta cells and is frequently asso-
ciated  with  diabetes  and/or  glucose  intoler-
ance. Au et al.68 studied pancreatic MRI-T2* in
thalassemia major patients with and without
diabetes. Pancreatic T2* signals were abnor-
mal in 80% of patients in both groups, but dia-
betic patients had a smaller pancreas volume
(P<0.0001).  In  normoglycemic  patients,  log-
pancreatic T2* values correlated with homeo-
static  model  assessment  HOMA-B  (beta  cell
reserve),  HOMA-IR  (insulin  resistance)  and
fasting insulin/C-peptide levels. In a longitudi-
nal  study  of  131  patients  with  thalassemia
major pancreatic and cardiac R2* were corre-
lated  (r2=0.52),  with  significant  pancreatic
iron  occurring  earlier  than  cardiac  iron.69
Based on these results, pancreatic R2* meas-
urements can be considered a useful marker
for future cardiac iron deposition allowing to
plan an appropriate iron chelation therapy.
Iron deposition in other organs and tissues
has not yet been extensively examined.  
Oral iron chelators
Survival of patients with thalassemia major
depends  on  long  life  red  blood  cell  transfu-
sions that inevitably lead to the accumulation
of  iron  in  the  body.  Excess  iron  is  toxic
because it generates free radicals and induces
oxidative  stress  resulting  in  cell  and  organ
damage. Excess iron from transfusions is dis-
tributed initially to macrophages and to the
liver,  then  iron  accumulates  into  the
endocrine  organs  and  heart  causing,  if  not
treated, the complications typically associated
with  iron  overload,  such  as  hypogonadism,
hypothyroidism,  hypoparathyroidism,  dia-
betes, liver fibrosis and early death usually for
cardiac failure. The aims of iron chelation are
to reduce dangerous excess iron to safe iron
levels, to maintain currently acceptable levels,
to minimize exposure of tissues to the toxic
free iron and possibly to prevent iron accumu-
lation.  Deferoxamine  (DFO),  the  first  iron
chelator, was developed  more than 40 years
ago and has been shown to decrease morbidi-
ty from iron overload and to prolong life in
patients who comply with therapy. Due to its
high  molecular  weight  ad  its  short  half-life
(approximately 20 min) DFO must be admin-
istered by parenterally route (usually subcuta-
neous), 8 to 12 hours/day, 5 to 7 days/week.
This demanding regime results in poor adher-
ence to therapy limiting the efficacy of this
chelator  in  a  significant  proportion  of
patients.  As  a  consequence  the  search  for
more practical orally available chelators has
been a major challenge during the last few
decades.
Deferiprone
Deferiprone (1,2 dimethyl-3-hydroxypyrid-4-
one)  (DFP)  was  synthesized  in  1984  at  the
University of Essex in London and was first
used in humans in 1987. The compound was
initially screened in cell lines and subsequent-
ly tested in animal models of iron overload,
proving that it was absorbed by gastrointesti-
nal  (GI)  apparatus  and  caused  excretion  of
excess iron. DFP is a bidentate chelator, there-
fore three DFP molecules are required to bind
the  six  coordination  sites  of  an  iron  atom
(Fe+++ ) (Figure 7) DFP has strong iron-bind-
ing  capacity  particularly  for  ferric  iron
(pFe+++=19.6) and is rapidly absorbed after
oral  administration,  reaching  plasma  level
peak about 1 hour after giving medication.72
Most of the iron DFP complex is excreted in
the urine and a minimal amount in the feces.
Due to the relatively short half-life (160 min)
and the rapid glucuronidation into an in active
metabolite, DFP requires thrice-daily adminis-
tration.73 Although the most used dose is 75
mg/kg/day, DFP can be given safely up to 100
mg/kg/day  according  to  the  severity  of  iron
overload and to the patient’s tolerability.
Deferiprone efficacy
The purpose of an effective iron chelation
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Figure  6.  Cardiac  MRI  in  patients  with
thalassemia  major.  A.  Severe  liver  and
heart iron. B. Severe liver iron and normal
heart iron (courtesy of Dr. G. Matta).[Pediatric Reports 2011; 3:e17] [page 71]
therapy is to prevent or reduce body iron accu-
mulation. In regularly transfused patients the
rate  of  iron  accumulation,  originated  from
destroyed  senescent  red  cells,  is  0.3-0.5
mg/kg/day. Therefore, a chelator should be able
to remove at least this amount of iron to mini-
mize the risk of iron-induced toxicity.
Several studies have shown that DFP, at com-
parable doses has an efficacy similar to that of
DFO, and that iron excretion increases with the
dose and with the degree of iron overload (Grady
R. personal communication).73,74 DFP at appro-
priate doses is able to decrease or stabilize body
iron as assessed by sequential serum ferritin or
liver iron concentration, despite repeated RBC
transfusions.75-77 Several  independent  studies
have shown that DFP is more effective than DFO
in  removing  cardiac  iron,  improving  cardiac
function and reducing mortality for cardiac dis-
ease.51,78-80 The  most  comprehensive  results
have been obtained in a large prospective trial,
where 61 patients with moderate cardiac iron
load  (T2*  between  10  to  20  ms),  previously
chelated  with  DFO  where  randomized  to  be
maintained on DFO or switched to DFP.51After 12
months of treatment a significant improvement
in myocardial T2* was observed with both treat-
ments, but the improvement was greater with
DFP than with DFO [+27% vs 13% (P=0.023)].
Left ventricular ejection fraction also increased
significantly, more in the DFP group [3.1% vs
0.3%(P=0.030)]. DFP treatment showed a signif-
icant greater cardiac protection as compared to
DFO in a large natural history study on survival
and  causes  of  death  in  patients  from  seven
Italian thalassemia centres.80The study included
cardiac events and survival for 359 patients on
DFO, during 8 years of observation and for 157
patients switched from DFO to DFP. At the base-
line, the two groups were comparable for age and
sex, while serum ferritin was significantly high-
er in patients switched to DFP (mean serum fer-
ritin 1860 vs 1460 ʼg/L, P<0.001). DFP- switched
patients did not experience any cardiac event,
whereas 52 cardiac events, including 10 cardiac
deaths, occurred in patients on DFO. The greater
efficacy of DFP in removing excess cardiac iron
may be due to some pharmacochemical charac-
teristics of DFP, such as low molecular weight,
neutral charge and lipophilicity, which facilitate
myocyte  membrane  crossing  and  chelation  of
intracellular iron.81
Deferiprone and Deferoxamine
association
DFP  and  DFO  can  be  given  to  the  same
patient with different regimes: in combination
on the same day, either simultaneously (i.e.
DFP given before breakfast, lunch and dinner
and DFO infused during the day) or sequen-
tially  (i.e.  DFP  as  above  and  DFO  infused
overnight), or as alternate treatment (i.e. one
or  the  other  chelator  is  given  on  different
days). Combination therapy is considered an
intensive chelation regimen and usually DFP
is administered every day, while subcutaneous
DFO is given 2 to 7 days/week, according to the
severity of iron overload. In patients with heart
failure,  to  reinforce  chelation,  DFO  can  be
given  intravenously  24  h/day.  The  potential
advantages  of  the  combined  chelation  are
reported in Table 4. Several single case reports
and prospective studies have shown that com-
bined intensive chelation is effective in reduc-
ing cardiac siderosis and in improving cardiac
function  in  patients  with  severe  heart  iron
overload and heart failure.82-85 A randomized,
placebo-controlled, double blind study suggest-
ed that in comparison to the standard chela-
tion with DFO, combination therapy with DFO
and  DFP,  was  able  reduce  myocardial  iron
(ratio  of  change  in  cardiac  T2*  geometric
means 1.5 in combined therapy vs 1.24 in DFO
monotherapy, P=0.02) and improve LVEF (2.6%
vs 0.6% P=0.05).52 In a study from Greece,
reversal of endocrine complications, with very
intensive  combined  chelation  (DFP  75-100
mg/kg/day  and  DFO  20-60  mg/kg/day),  has
been reported.86 In particular, abnormal glu-
cose metabolism was normalized in 17 (44%)
of 39 patients. In 18 patients requiring thyrox-
ine  supplementation  for  hypothyroidism,  10
were able to reduce their thyroxine dose. In 14
hypogonadal males on testosterone therapy, 7
stopped treatment and quite remarkably, 6 of
19  females,  who  were  hypogonadal  on  DFO
monotherapy,  were  able  to  conceive.
Combination  therapy  has  been  shown  to
improve survival in patients with thalassemia
major.
In 1999 combination therapy was introduced
in Cyprus because of the increased trend of
deaths for cardiac disease, despite the use of
intensive  intravenous  DFO  in  patients  at
increased risk of heart failure.49,87 The analy-
sis of the survival trends from 1985 to 1999 and
after  2000,  showed  a  significant  reversal  of
this  trend  in  mortality  for  cardiac  disease.
None of the patient on combination therapy
died  for  cardiac  disease.  Alternate  chelation
efficacy has been prospectively evaluated in a
study  where  60  thalassemia  major  patients,
regularly chelated with DFO, were randomized
to  continue  DFO  alone  or  to  receive  5
days/week  DFP  and  2  days/week  DFO  for  1
year.88 Comparable efficacy on serum ferritin
and liver iron concentration was observed in
both  treatment  groups.  More  recently,  in  a
large long-term (5 years of follow-up), multi-
center study, 213 patients were randomized to
receive DFO for 4 days/week and DFP for the
remaining 3 days, or DFP monotherapy  for 7
days/week.89 In  the  alternating  treatment
group  serum  ferritin  showed  a  significant
reduction  (P=  0.005)  as  compared  to  DFP
group.  DFO  monotherapy  versus  DFP
monotherapy, alternate or combined DFO-DFP
regimes, have been evaluated in another long-
term, multicenter, randomized trial including
265 patients.90 None of the patients on DFP
alone  or  in  combined  treatment  died,  one
death occurred with alternate treatment and
10 deaths with DFO treatment.
Deferiprone safety profile
Gastrointestinal  symptoms  (GI)  (nausea,
vomiting, abdominal pain) are the most com-
monly reported DFP-related adverse events. In
a  prospective  long-term  study  187  patients
where monitored for 4 years.91 GI symptoms
occurred in 33% subsequent years. In general
these symptoms were mild or moderate and
only a restricted number of patients discontin-
ued therapy. Similar results have been report-
ed in other studies.73,92 A lower incidence of GI
adverse  events  (vomiting  6%  of  patients,
abdominal pain 6% and nausea 1%) has been
described in patients taking the new DFP liq-
uid  formulation.93 Arthropaty,  particularly
involving the knees, has been associated with
the use of DFP in a variable number of patients
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Table 4. Potential advantages of combina-
tion therapy.
Access to different iron pools
Greater efficacy
Dose decrease®toxicity decrease
Chelation of toxic free iron
Better tolerability and compliance
Figure 7. Structure of the deferiprone/iron
complex. Three molecules of deferiprone
bind one iron atom (yellow).[page 72] [Pediatric Reports 2011; 3:e17]
(3.9-20%).91,92 A particularly high incidence of
arthropaty, reported in Indian patients (up to
41%), has been attributed to the severe iron
overload or undefined etnicHeading 2 genetic
background.94 Unlike GI problems, which usu-
ally appear in the first weeks of treatment, the
onset of joint symptoms may be late, even after
years  of  treatment.  The  symptoms,  usually
mild, resolve in a few days with non-steroid
anti-inflammatory drugs, or temporary discon-
tinuation of DFP or dose reduction.95Transient
and  mild  to  moderate  increase  in  liver
enzymes has been reported in about 7% of the
patients,  particularly  in  the  first  months  of
treatment. However, ALT monitoring at regular
intervals is recommended and DFP interrup-
tion or dose reduction should be considered if
ALT  levels  are  significantly  and  persistently
elevated. 
The most serious side effect associated with
DFP  use  is  agranulocytosis  [absolute  neu-
trophil count (ANC) lower than 0.5ﾥ109/L]. In
controlled studies it occurred in about 1% of
the  patients  (0.2-0.3  episodes  per  100
patient/years) usually within the first year of
treatment.91,92,96 Agranulocytosis is reversible
with interruption of DFP, but treatment with G-
CSF may be needed for faster recovery. Deaths
from severe infectious associated with DFP-
related agranulocytosis have been reported in
some  patients.97 Weekly  ANC  monitoring  is
recommended to detect early signs of agranu-
locytosis. Moreover, patients should be coun-
selled to stop DFP in case of fever and report to
their  physician  any  symptom  indicative  of
infection.  For  the  high  risk  of  recurrence,
rechallenge with DFP is not recommended in
patients  who  developed  agraulocytosis.  Mild
neutropenia  (ANC  between  0.5-1.5ﾥ109/L)
occurs in 3.6-8.5% of the patients, more com-
monly in non-splenectomized patients and in
association with viral infections.73,91,92,96 This
condition is usually reversible with discontinu-
ation of the drug.
Deferasirox
Deferasirox (DFX) is an oral iron chelator,
administered as a suspension, that has been
developed by computer modelling, after evalu-
ation of more than 700 compounds from sever-
al chemical classes. It belongs to a new class of
tridentate chelators, binding iron in a 2:1 ratio
(Figure 8). DFX-iron complexes are primarily
excreted with feces.98 DFX underwent exten-
sive safety testing and clinical trials including
several thousands of patients worldwide.99-105
The plasma half-life of 8 to 16 hours supports
once-daily  administration  and  scavenging  of
non-transferrin-bound labile plasma iron, the
toxic form of iron responsible of tissue dam-
age.106  DFX  is  currently  approved  in  many
countries  for  the  treatment  of  chronic  iron
overload, associated with blood transfusions in
patients older than 2 years. However, a small-
scale study indicated that DFX may be suitable
for controlling iron levels also in non-transfu-
sion  dependent  patients  with  thalassemia
intermedia.107
Deferasirox efficacy
Efficacy of DFX has been evaluated in large
and long-term clinical studies in pediatric as
well as adult patients.107-110 Serum ferritin and
LIC  monitoring  in  these  studies  have  high-
lighted the importance to achieve the thera-
peutic goal of adjusting the dose of DFX on the
basis of transfusional iron intake.93,111 In one-
year studies, the proportion of patients in neg-
ative iron balance at 20 mg/kg/ day of DFX was
75% for those at low transfusional iron input
(<0.3  mg/kg/day),  falling  to  55%  and  47%
respectively  at  intermediate  (0.3  to  0.5
mg/kg/day) and high (>0.5 mg/kg/day) transfu-
sional iron input. The highest recommended
dose initially approved by health authorities in
many countries was 30 mg/kg/day. A retrospec-
tive analysis of the extension phases of the
core studies, investigated the efficacy (based
on changes in serum ferritin levels) and safe-
ty of DFX doses higher than 30 mg/kg/day in
adult  and  pediatric  patients  with  different
transfusion  dependent  anemias  (i.e.  tha-
lassemia,  sickle  cell  anemia,  myelodispla-
sia).108 In the overall population there was a
statistically  significant  median  decrease  in
serum ferritin of 440 mg/L (P<0.0001) from
pre-dose-escalation  to  the  time-of-analysis,
with no safety concerns (see below). Similar
results  have  been  obtained  in  two  large
prospective studies.107,109 DFX has been also
evaluated long-term in pediatric patients with
thalassemia  major.112-114 In  24  out  of  40
patients enrolled to receive DFX for 5 years,
LIC was reduced in a dose-dependent manner.
Clinical data support the efficacy of DFX in
removing cardiac iron and preventing myocar-
dial  siderosis  in  patients  with  thalassemia
major.67,115,116 In a one year prospective multi-
center trial (EPIC cardiac substudy), DFX signif-
icantly  improved  geometric  mean  myocardial
T2*  from  baseline  11.2  to  12.9  ms  (+16%,
P<0.0001), with significant concomitant reduc-
tion in both serum ferritin and LIC.111 The two
years extension of the same study showed  con-
tinued improvement in myocardial T2* from the
baseline 11.2 to 14.8 ms (P<0.001). In these
studies  the  majority  of  the  patients  received
doses of DFX higher than 30 mg/kg/day. In par-
ticular  at  the  end  of  two  years  53.5%  of  the
patients  were  receiving  40  mg/kg/day,  9.9%
were receiving 45 mg/kg/day and 2 were receiv-
ing  47  and  51  mg/kg/day,  respectively.116  It
should  be  pointed  out  that  overall  LVEF
remained stable and in the normal range over
the  two  years  (67.5±5.7%  at  baseline;
67.7±5.1% at two years; P=0.72), but 5 patients
developed LVEF less than 56% (the lowest nor-
mal value in thalassemia major patients) dur-
ing the trial.116 As DFX is an oral, once-day easy
to take iron chelator, compliance is expected to
be high. Several studies, which have specifical-
ly  assessed  patient  preference,  demonstrated
satisfaction and convenience with DFX therapy,
which  may  translate  into  improvements  in
patient compliance and increased effectiveness
of chelation therapy.117-119
Deferasirox and Deferoxamine
association
Preliminary  promising  results  have  been
obtained with iron balance studies, which eval-
uated  the  total  (i.e.  fecal  and  urinary)  iron
excretion, in three patients treated with DFX
and DFO in combination.120 Total iron excre-
tion was synergistic (i.e. higher than the sum
of  iron  excretion  obtained  with  each  single
drug) in two patients, but less than additive in
the third patient, who responded the best to
both drugs individually.
Alternating  treatment  with  DFO  and  DFX
resulted to be safe and effective in two retro-
spective studies including a limited number of
patients.121,122
Safety 
Gastrointestinal  symptoms  (i.e.  nausea,
vomiting, diarrhea, abdominal pain) and skin
rash  are  the  most  common  DFX-related
adverse events, reported in the core pre-regis-
tration trials in 15% and 11% of the patients,
respectively.123 The symptoms were mild and
usually transient, though some severe cases
required  dose  interruption  and/or  adjust-
Review
Figure 8. Structure of the deferasirox. Two
molecules of deferasirox bind one atom of
iron.[Pediatric Reports 2011; 3:e17] [page 73]
ments.124(Exjade  International  website
www.exjade.com)  About  one  third  of  the
patients have shown increases in serum crea-
tinine, rising above the mean of the pre-treat-
ment  levels  by  >33%  on  two  consecutive
assessments.107 These increments were dose-
dependent and non-progressive in study exten-
sions up to 4.5 years.125 However, DFX should
be  interrupted  if  serum  creatinine  shows  a
progressive  rise,  beyond  the  age-appropriate
upper  limit  of  normal  (Exjade  International
website  www.exjade.com/exjade-safety/long-
term-safety-profile.jsp)  Elevations  of  liver
transaminases have been reported in about 2%
of patients and were not dose dependent. No
worsening of renal or liver function has been
observed following dose escalation (i.e. doses
of DFX higher than 30 mg/kg/d) in a retrospec-
tive study including a large number of pedi-
atric  and  adult  patients  with  transfusion-
dependent  anemias.112 In  the  long-term  (<5
years of treatment) trial conducted in pediatric
patients, DFX was generally well tolerated.116
No signs of impaired growth or sexual develop-
ment  and  no  evidence  of  progressive  renal,
hepatic or bone marrow dysfunction have been
reported. However, reports of renal tubulopa-
thy (Fanconi syndrome) reversible with DFX
cessation, have been recently described main-
ly in pediatric patients with low serum ferritin
levels.126,127
Iron  Chelation  therapy  has  significantly
improved in the recent years. This improve-
ment  is  mainly  due  to  greater  chelation
options and the possibility of accurately assess
specific organ iron overload. The ability to rec-
ognize preclinical cardiac iron deposition by
MRI and the availability of effective chelation
regimes  has  significantly  reduced  cardiac
deaths. DFP resulted to be particularly useful
in reversing and preventing cardiac disease,
alone and in combination with DFO. The car-
diac profile of DFX is less well characterized,
but the efficacy of this drug in reducing and
controlling body iron overload has been clearly
documented.
Despite both oral iron chelators showed a
manageable  safety  profile,  close  monitoring
for adverse events is recommended.
Gene therapy
Continuous improvements in the traditional
care  of  β-thalassemia  has  ameliorated  the
quality  of  life  and  greatly  improved  the  life
expectancy.128-130 Despite these results, until
recently  a  definitive  cure  could  only  be
achieved  with  bone  marrow  transplantation
(BMT)  from  related  or  unrelated  donors.
However, BMT is only available for a minority
of patients and bears a significant risk of mor-
tality and morbility, especially when the donor
is unrelated131 or only aploidentical.132 In the
search for a more general and definitive cure,
hematologists have pursued alternative strate-
gies aimed at correcting the defective β-globin
gene by either gene transfer of a normal β-glo-
bin gene or substitution of the defective gene
by homologous recombination.  Although gene
therapy would have been theoretically possible
soon  after  the  discovery  and  cloning  of  the
human globin genes, for many years two main
obstacles have hampered the progress in this
field.133 The  first  obstacle  has  been  the
extremely  complex  regulation  of  the  globin
genes that has taken decades to at least par-
tially unravel.  The second and equally impor-
tant obstacle has been the lack of an optimal
vector  for  gene  transfer  into  quiescent
hematopoietic stem cells (HSC).  
Traditional retroviral vectors
For at least two decades after the cloning of
the globin genes, many different virus were
explored as possible gene therapy vectors with
very  limited  success.  Moloney  murine
leukemia retrovirus based globin vectors were
the only vectors able to infect HSCs, but they
did it at a very low rate133-134 and, even worse,
they were so unstable that the transduced glo-
bin gene only rarely integrated intact into the
genome, thus losing any therapeutic efficacy.
In fact, the regulatory sequences of the locus
control region (LCR) needed to express high
levels  of  globin,  bore  an  intrinsic  instability
such that the traditional retrovirus globin vec-
tors always displayed an inverse relationship
between  the  amount  of  regulatory  elements
included  in  the  vector  and  the  final  viral
titer.135 Despite the failure in obtaining high
level  and  persisting  gene  expression,  those
long frustrating years were not spent in vain as
much more efforts were put to discover and
assemble  the  optimal  globin  regulatory
sequences. 
Gene therapy with lentiviral globin
vectors
Globin  gene  therapy  perspectives  changed
abruptly close to the year 2000 when lentiviral
based vectors were first introduced.  The major
advantages of these vectors were the ability to
infect  quiescent  hematopoietic  stem  cells  at
higher rates and to export unspliced the vector
RNA from nuclei, thereby ensuring the integrity
of the expression cassette. In the year 2000, the
group led by Sadelain published the first study
in which a murine model of thalassemia inter-
media was efficiently cured with a lentiviral glo-
bin  vector.136 Soon  after,  therapeutic  efficacy
was demonstrated in a murine model of sickle
cell disease137 and even in a murine model of
thalassemia major developed by transplanting
fetal  livers  from  homozygous  Th3/Th3  tha-
lassemic  mice  into  irradiated  normal  adult
mice.138 In the following years different labora-
tories  confirmed  and  extended  initial  results
demonstrating efficacy of lentiviral gene thera-
py with xenotransplants of genetically corrected
human thalassemic HCSs into recipient SCID
mice.139 All these experiments used essentially
the same lentiviral vector with only minor mod-
ifications. In the beginning the vector was a
second generation lentivector, but, in view of
the possible translation into clinical practice, to
increase safety by reducing the chance to pro-
duce unwanted replication competent lentiviral
particles, most of the laboratories replaced sec-
ond140with third generation lentiviral vectors141
as developed by Naldini et al. (Figure 9). The
globin cassette of the vector is generally made
of the beta-globin gene deleted of a destabiliz-
ing RsaI fragment contained in intron 2.142 The
first gene therapy study used a long 600 bp β-
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Figure 9. General scheme of 3rd generation globin lentiviral vectors. Vectors have dele-
tions of all dispensable and potentially harmful HIV sequences (tat, vif, vpr, vpu, nef).
The partial ORF of GAG that can not be removed because overlaps the packaging signal
(Y) contains 2 in frame stop codons. The 400 bp deletion in the U3 region blocks
provirus  transcription after chromosomal integration (self inactivating vector). POL-
GAG , REV and VSV-G envelopes are provided in trans to avoid recombination that could
reconstitute wild type replication competent HIV particles. The b-globin cassette in the
current vectors contains from 2 to 4 HSs, β-globin promoters of 260-600 bp, a stabiliz-
ing RsaI deletion of IVS2, variable length of the 3’ UTR and an enhancer region con-
tained in a PstI fragment 3’ to the β-globin gene. As an additional safety feature some
vector are insulated with the chicken HS4 or other equivalent insulator. Insulators that
are inserted into the 3’ U3 region are duplicated and moved to the 5’ U3 region during
viral reverse transcription achieving insulation of both sides of the vector. Insulation is
expected to restrict the activity of the internal LCR enhancer to the globin cassette and
to create a barrier to the invasion of adjacent heterochromatin that ensures persistent
expression. ORF, Open reading frame; GAG, group-specific Antigen; 3’ UTR, 3’ untrans-
lated region; LCR, locus control region.[page 74] [Pediatric Reports 2011; 3:e17]
globin  promoter,  whereas  other  studies  pre-
ferred  to  use  a  shorter  promoter  version  of
approximately 270 bp.  Person’s group demon-
strated good efficacy of a β-globin vector driven
by the β-globin promoter and regulated by LCR
sequences.143 All globin cassettes contained a
small PstI DNA fragment thought to contain a 3’
β-globin enhancer. Several sequences around
the DNAse I hypersensitive sites that make up
the LCR are absolutely required to attain good
levels of globin expression and are therefore
included  in  all  constructs  for  gene  therapy.
However,  the  number  and  the  length  of  the
DNAse I HS sites differ in all globin cassettes,
reflecting  the  difficulty  to  localize  the  really
important regulatory sequence within each HS,
while  omitting  potentially  destabilizing  ele-
ments.  In  their  ground  breaking  experiment,
Sadelain’s  group  provided  evidences  that  the
fragments  larger  than  the  core  HS  elements
were needed to ensure elevated and long term
gene  expression  of  the  transduced  β-globin
gene.144 Since then, most of the vectors includ-
ed larger versions of the HSs 2-3-4, but recently
Miccio et al. demonstrated good efficacy of a β-
globin cassette bearing only HS2 and 3.145 On
the  other  hand,  even  though  human  natural
deletions that occurred in perfectly healthy sub-
jects, suggest that HS1 could be omitted, recent
studies showed that mice transplanted with glo-
bin cassette that included the HS1 did better
than mice in which HS1 was omitted from the
cassette.146 Finally, some of the vectors in use
are flanked by insulators, such as the chicken
HS4 insulator, to constrain the enhancing effect
of the LCR to the globin transgene, while ham-
pering the invasion of heterochromatin and the
silencing of the transgene from the neighboring
chromatin.147
Success in the first human gene
therapy trial for β-thalassemia
After many animal experiments, in the year
2006, the first human gene therapy trial for β-
thalassemia and sickle cell disease began in
France. The first patient treated failed for tech-
nical reasons to reconstitute with the gene-
corrected bone marrow and required back up of
its own thalassemic bone marrow. The second
patient, transplanted in June 2007 at age 18,
has been recently reported to be free of trans-
fusions now after 40 months of post-transplant
follow up.148 The patient was a compound  het-
erozygous HbE/β°-thalassemia with the phe-
notype of β-thalassemia major and regularly
transfused  since  childhood.  He  lacked  any
available related or unrelated donor and met all
criteria for inclusion in the gene therapy trial.
The  patient  was  prepared  for  gene  transfer
with  myelo-suppressive  doses  of  Busulfan
(3.2mg/kg/da for 4 days)and transduced with a
lentiviral vector already validated in the gene
therapy of a murine model of sickle cell dis-
ease.  The  vector  bore  an  antisickling  β-glo-
bin(βA(T87Q)), a short 260 bp globin promot-
er, HSs 2, 3, 4 and 2 copies of the chicken core
insulator  flanking  the  globin  cassette.  The
choice of a modified β-globin gene aimed at
correcting anemia while antagonizing sickling
and  permitting  discrimination  of  the  globin
produced by the vector from the endogenous
derived β-globin chain.
In  the  months  following  gene  transfer  the
patient required less and less transfusions until
he became totally transfusion independent at 12
months  post-transplant  remaining  so  since
then  for  over  30  months.  Since  the  time  he
became  transfusion  independent,  the  patient
was  able  to  maintain  a  hemoglobin  level
between 9 and 10 gr/dL. Hemoglobin synthesis
analysis at the steady state level showed that
the vector produced 1/3rd (3.0 gr/dL) of the total
hemoglobin, the remaining 2/3rd were account-
ed for by HbF and HbE in equal parts. Hence, in
this  patient  a  transfusion  independent  state
was reached not only because of the supplemen-
tary 3 grams of exogenous hemoglobin, but also
through a partial reactivation of the fetal γ-glo-
bin gene.  Since fetal hemoglobin is genetically
controlled, the increase observed in this patient
may be an advantage restricted only to selected
patients and not necessary related to the gene
therapy procedure.  Follow up analysis in the
patient, discovered a dominant cell clone with
integration site into the HMGA2 gene, a poten-
tial  oncogene.149,150 In  erythroblasts,  clonal
dominance reached a plateau when accounting
for 77% of the integration sites at 20 months
post-transplantation. The patient continues to
be strictly monitored to anticipate a potential
evolution into a leukemic state. However, stud-
ies  suggest  that  isolated  over  expression  of
truncated  HMGA2  is  mainly  associated  with
benign tumors or conditions such as lipomas or
paroxysmal  nocturnal  hemoglobinuria.
Although HMGA2 can also be associated with
malignant  tumors,  the  latter  are  tought  to
derive from a more complex dysregulation of
several oncogenes (HMGA2, myc and ras) that
are probably activated by deletions or inactiva-
tion of the let7 miR gene.151 In summary, the
first  gene  transfer  experiment  in  a  β-tha-
lassemia patient proves that gene therapy can
succeed even in humans and represents a mil-
iary stone in the road of gene therapy toward a
definitive  cure  for  all  thalassemia  patients.
However, the parallel increase in fetal hemoglo-
bin observed in the patient may suggest that
other favorable modifying factors might have
contributed  to  the  therapeutic  effect  in  this
individual case. Furthermore, the emergence of
a dominant HMGA2 positive cell clone, although
so  far  harmless,  casts  a  worrisome  shadow,
which only a more extended follow up should
clear. Hence, larger number of patient are need-
ed to confirm the initial positive results as well
as to assure that the globin lentiviral vectors are
sufficiently  safe  and  offer  to  thalassemia
patients  a  better  option  than  the  traditional
transfusion and chelation therapy.  
Therapeutic perspectives using iPS
cells
In  the  last  years,  a  new  highly  promising
technology that allows derivation of patient spe-
cific embryonic–like stem cells from adult dif-
ferentiated  cells  has  been  developed.  These
cells, produced by transduction with the tran-
scription factors Sox2, Oct3/4, Myc and Klf4, are
called  induced  pluripotent  stem  cells  (iPS)
because have the ability to differentiate into all
embryonic tissues except extra-embryonic tis-
sues. iPS can be easily obtained and have the
great advantage of being expandable in large
amounts and indefinitely.  However the feature
that makes them highly attractive in the field of
gene  therapy  is  the  possibility  of  being
amenable  to  gene  correction  by  homologous
recombination. A proof of principle of this use
has been recently provided by employing iPS to
correct a murine model of sickle cell anemia. In
this experiment, iPS were derived from fibrob-
last harvested from a skin biopsy and induced to
become iPS by transduction with retroviral vec-
tors that encode four stem cell transcription fac-
tors.  The sickle cell defect was then corrected
by  standard  homologous  recombination  and,
after  in  vitro  differentiation  of  iPS  into
hematopoietic  stem  cells,  were  transplanted
back into the original mouse donor, curing its
SC disease. Another possible use of iPS is to
overcome the risk of insertional mutagenesis by
combining genetic and cell therapy.152 In this
approach patient specific iPS cells are subjected
to gene transfer and clones are selected based
on the safety and the level of expression at the
site of vector integration.  Upon differentiation
of such clones into hematopoietic stem cells, it
should be possible to transplant back the autol-
ogous cells without the adverse effects linked to
the  random  chromosomal  integration  of  the
vector .
Presently,  iPS  based  techniques  have  the
drawback  of  requiring  potentially  oncogenic
retrovirus and oncogenic transcription factors
to induce the iPS state.  However the technolo-
gy has being continuously improved in several
respects mainly with the goal of reducing their
oncogenic potential.  Accordingly, iPS can be
now derived with only transient expression of
the reprogramming factors or by excision of the
factors  after  reprogramming.  It  is  however
important to note that it is unknown whether
the  genomic  integrity  of  the  reprogrammed
cells and reprogramming itself are consistent
with safe and long-term hematopoietic reconsti-
tution.  The  field  is  very  exciting  and  rapidly
developing and in the next future has the poten-
tial  to  completely  revolutionize  the  field  of
genetic therapy and regenerative medicine.
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